Who are Hetrombopag Olamine+Standard Therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nplate, Promacta, eltrombopag combining rituximab, Avatrombopag Oral Tablet, Eltrombopag (EPAG), rhTPO combined with Herombopag + CsA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hetrombopag-olamine-standard-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Hetrombopag Olamine+Standard Therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hetrombopag Olamine+Standard Therapy (Hetrombopag Olamine+Standard Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombopoietin receptor agonist. Area: Hematology.

phase 3 Thrombopoietin receptor agonist TPO receptor (c-Mpl) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Hetrombopag Olamine+Standard Therapy (Hetrombopag Olamine+Standard Therapy) — Jiangsu HengRui Medicine Co., Ltd.. Hetrombopag olamine is a thrombopoietin receptor agonist that stimulates platelet production to increase platelet counts.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hetrombopag Olamine+Standard Therapy TARGET	Hetrombopag Olamine+Standard Therapy	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Thrombopoietin receptor agonist	TPO receptor (c-Mpl)
Nplate	ROMIPLOSTIM	Amgen	marketed	Thrombopoietin Receptor Agonist [EPC]	Thrombopoietin receptor	2008-01-01
Promacta	ELTROMBOPAG	Novartis	marketed	Thrombopoietin Receptor Agonist	Thrombopoietin receptor	2008-01-01
eltrombopag combining rituximab	eltrombopag combining rituximab	Institute of Hematology & Blood Diseases Hospital, China	marketed	Combination therapy: thrombopoietin receptor agonist + monoclonal antibody	TPO receptor (c-Mpl) and CD20
Avatrombopag Oral Tablet	Avatrombopag Oral Tablet	Sobi, Inc.	marketed	Thrombopoietin receptor agonist	TPO receptor (c-Mpl)
Eltrombopag (EPAG)	Eltrombopag (EPAG)	Centro de Atencion e Investigacion Medica	marketed	Thrombopoietin receptor agonist	TPO receptor (c-Mpl)
rhTPO combined with Herombopag + CsA	rhTPO combined with Herombopag + CsA	Peking Union Medical College Hospital	marketed	Thrombopoietin receptor agonist combination with immunosuppressant	Thrombopoietin receptor (MPL); calcineurin (CsA target)

Recent regulatory actions (last 90 days)

2026-03-16 — Promacta · FDA · approved · US · Novartis

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombopoietin receptor agonist class)

Centro de Atencion e Investigacion Medica · 2 drugs in this class
Institute of Hematology & Blood Diseases Hospital, China · 2 drugs in this class
Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
Hvidovre University Hospital · 1 drug in this class
Kyowa Kirin Korea Co., Ltd. · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class
PharmaEssentia Japan K.K. · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Shenyang Sunshine Pharmaceutical Co., LTD. · 1 drug in this class
Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hetrombopag Olamine+Standard Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/hetrombopag-olamine-standard-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab